The clinical problem the material targets is stubbornly common. Autologous bone grafting remains the gold standard, but it carries donor site morbidity, limited graft supply, and surgical risk. Injectable hydrogels can conform to irregular defects through minimally invasive delivery, yet they are typically too soft for load-bearing applications and often require external triggers such as photo-crosslinking to stiffen. The new material, built from regenerated silk fibroin, tyramine-modified carboxymethyl cellulose, and a hybrid of MXene nanosheets with cellulose nanofibers, sidesteps that limitation by maturing autonomously once inside the body.

The self-reinforcement mechanism is a story of molecular choreography. After the precursor solution is injected, an enzymatic horseradish peroxidase and hydrogen peroxide system triggers phenolic crosslinking of the tyramine-modified cellulose, gelling the material in roughly 100 to 300 seconds depending on formulation. Over the following days, the confined environment created by the cellulose network restricts the mobility of silk fibroin chains, nudging them from random coils into aligned beta-sheet crystalline domains. Meanwhile, the MXene-cellulose nanosheets act as templates, offering abundant hydrogen-bonding sites that guide the orientation of those beta-sheets along their surfaces. The result is a progressively ordered, densely packed network whose compressive modulus climbs nearly tenfold, from about 0.08 megapascals at day zero to roughly 0.85 megapascals by day five.

That mechanical trajectory matters because it is rare. In an Ashby plot comparison against other self-reinforcing injectable hydrogels reported in the literature, the optimized formulation occupied a distinctly superior region of the mechanical-injectability landscape. The gel also demonstrated practical shape-filling, uniformly occupying an irregular defect carved into a porcine femur, and it retained more than 90 percent of its dry weight after 28 days of degradation testing, with moderate swelling between 160 and 180 percent. Implanted samples harvested at 14 and 28 days kept their compressive strength, suggesting the material holds the line during the critical early window of repair.

The electrical side of the design is equally deliberate. Bone’s native piezoelectricity arises from collagen and mineral converting mechanical stress into charge, and the team sought to recreate that transduction within a soft matrix. Rather than relying on rigid piezoelectric ceramics like barium titanate or zinc oxide, which aggregate and resist biodegradation, the researchers used Ti3C2Tx MXene modified with cellulose nanofibers. Spectroscopic analysis showed hydrogen-bond-mediated coupling between the cellulose hydroxyl groups and MXene surface terminations, which improved interfacial polarization and produced a higher dielectric constant with lower dielectric loss in model composites.

Under cyclic compression at 0.1 megapascals, the hydrogel’s output scaled dramatically with both MXene-cellulose concentration and maturation time. The unmodified silk-cellulose gel produced only about 10 millivolts, but the optimized 0.4 percent MXene-cellulose formulation generated up to 60 millivolts by day seven, a signal that rose in lockstep with beta-sheet formation and dipole alignment. The composite achieved a piezoelectric voltage coefficient of 22.6 millivolts per meter per newton and a markedly increased figure of merit, while outputs remained stable over 100 seconds of continuous cycling and scaled nearly linearly with applied pressure. Piezoresponse force microscopy confirmed strong nanoscale amplitude and near-180-degree phase contrast, hallmarks of well-aligned piezoelectric domains. The authors note that because MXene is not a classical piezoelectric crystal, the response is best attributed to interface-mediated electromechanical coupling across the composite network rather than intrinsic crystal piezoelectricity.

Crucially, the generated signals fall within the biologically relevant range known to activate calcium signaling in bone-forming cells. In vitro, bone marrow mesenchymal stem cells and endothelial cells cultured alongside the mechanically activated hydrogel proliferated faster than those exposed to unstimulated gels, with stimulation at four compression cycles per minute proving optimal. Alkaline phosphatase staining and alizarin red mineralization assays showed the strongest early and late osteogenic differentiation in the stimulated group, and Western blotting plus quantitative PCR confirmed upregulation of RUNX2, osteopontin, and osteocalcin. Scratch wounds, Transwell migration, and tube-formation assays added that endothelial cells formed more extensive capillary-like networks under piezoelectric stimulation, with angiogenic genes including CD31, von Willebrand factor, and VEGF elevated, painting a pro-regenerative microenvironment on both the bone and vascular fronts.

The deepest finding, and the one that gives the study its subtitle, lies in the epigenetics. RNA sequencing revealed that piezoelectric stimulation shifted stem cells toward calcium signaling and histone acetylation programs. Fluo-4 calcium imaging showed a surge of intracellular calcium within 30 minutes of stimulation, and Western blots confirmed phosphorylation of CaMKII and CREB, the canonical calcium-dependent cascade. Downstream, the acetyltransferase P300 rose, and histone H3 lysine 9 acetylation, a reversible mark tied to transcriptional activation, climbed in a dynamic, time-dependent pattern that peaked around 24 hours before partially declining. Chelating calcium with BAPTA or inhibiting P300 with C646 abolished both the acetylation signal and the osteogenic boost, establishing causality rather than mere correlation.

To find which genes the acetylation actually switched on, the team performed CUT&Tag profiling of H3K9ac and integrated it with the transcriptomic data. The overlap pointed squarely at PTH1R, the parathyroid hormone 1 receptor, a central regulator of bone remodeling whose promoter showed enriched H3K9ac and whose mRNA and protein levels rose under stimulation but fell when P300 was blocked. Pharmacologically antagonizing PTH1R suppressed RUNX2, osteopontin, and osteocalcin expression and reduced mineralization even under active piezoelectric stimulation, completing a coherent mechanistic chain: mechanical load becomes electricity, electricity opens calcium channels, calcium activates P300, P300 acetylates histones, and acetylated chromatin unlocks PTH1R-driven osteogenic transcription.

The in vivo evidence sealed the story. In a rat femoral condyle defect model, micro-computed tomography at 6 and 12 weeks showed substantially greater bone mineral density, bone volume fraction, trabecular thickness, and trabecular number in the piezoelectric hydrogel group compared with controls, plain silk gels, or the non-piezoelectric composite. Fluorochrome double labeling revealed a higher mineral apposition rate, and histology showed dense trabecular architecture with robust collagen deposition. Immunohistochemistry confirmed elevated H3K9ac and PTH1R in the new bone, mirroring the in vitro cascade. Blood chemistry and organ histology showed no hepatic or renal abnormalities, and an ex vivo porcine bone model confirmed the implanted gel still produced repeatable voltage under bone-like loading. Together, the results sketch a material that does not merely plug a hole in the skeleton but actively speaks the skeleton’s native electrical language, converting each step a patient takes into an epigenetic instruction to rebuild.

Subject of Research: Injectable self-reinforcing piezoelectric hydrogel for bone defect regeneration via epigenetic regulation

Article Title: An Injectable and Self‐Reinforced Piezoelectric Hydrogel for Irregular Bone Defects Regeneration: Dynamic Epigenetic Regulation Approach

Article References: Huang, Y.-K., Li, J., Yang, M.-M., Jia, C., Gong, Q.-X., Yuan, G.-C., Zhou, D., Shen, W.-H., Chen, Z.-G., Dong, Z.-R., Huang, J.-W., Peng, J., Su, D.-H., Zhao, M.-D., Dong, J., & Jiang, L.-B. (2026). An Injectable and Self‐Reinforced Piezoelectric Hydrogel for Irregular Bone Defects Regeneration: Dynamic Epigenetic Regulation Approach. Advanced Science, Article e77911. https://doi.org/10.1002/advs.77911

Image Credits: AI Generated

DOI: 10.1002/advs.77911

Keywords: piezoelectric hydrogel, bone regeneration, MXene, silk fibroin, epigenetics, H3K9 acetylation, PTH1R, calcium signaling, stem cells, injectable biomaterials, tissue engineering, Injectable

The appeal of whitlockite, whose chemical formula is Ca18Mg2(HPO4)2(PO4)12, lies in features that other bone ceramics simply lack. Its magnesium ions are known to enhance angiogenesis during the early stages of bone regeneration, encouraging the growth of blood vessels that feed healing tissue. Its hydrogen phosphate groups, absent from better-known phases such as hydroxyapatite and beta-tricalcium phosphate, dissolve more readily, releasing the calcium and phosphate ions that new bone mineral needs. These properties have made whitlockite a leading candidate for bone grafts and regenerative scaffolds, but only if it can be produced reliably and at scale.

That has been the stumbling block. The established route is wet-chemical precipitation, which demands precise control of precursor concentration, pH, temperature, and aging time. One widely cited protocol requires roughly 90 degrees Celsius, a pH between 4 and 5, carefully tuned precursor ratios, and an aging step of about twenty hours, followed by annealing to improve crystallinity. Even then, the full process can stretch from several days to a week and may still yield unwanted byproducts such as hydroxyapatite. Solid-state methods based purely on heat treatment are faster in principle but produce particles tens of micrometers across, far larger than the nanoscale crystals that best mimic natural bone and its extracellular matrix.

The new work sidesteps these bottlenecks with intense pulsed light, or IPL, a technique that fires high-energy flashes from a xenon lamp lasting no more than twenty milliseconds. IPL has previously excelled at making metal nanoparticles and sintering printed electronics, but calcium phosphate ceramics posed a fundamental problem: as wide-bandgap materials, they barely absorb light, so a flash alone cannot heat them. The researchers solved this by depositing their precursors on carbon fiber paper, which acts as a microheater, absorbing the flash and transferring an intense thermal shock directly to the powder in contact with it.

The precursors themselves were deliberately chosen for their water content. Dicalcium phosphate dihydrate, also known as brushite, was mixed with magnesium hydroxide and cast onto the carbon substrate. When the flash struck, the carbon fiber surged to temperatures approaching 1600 degrees Celsius at the highest voltages tested, partially melting the precursors and allowing magnesium ions to diffuse into calcium sites. Crucially, the dehydration of the hydrated precursor released water vapor that became trapped at the dense powder-carbon interface, creating a transient, high-pressure, water-rich microenvironment. The team hypothesizes that this localized vapor pressure delays complete dehydration of the hydrogen phosphate groups, stabilizing them within the emerging whitlockite structure.

Finding the right operating window required systematic tuning. Grazing-incidence X-ray diffraction showed no crystalline product at 300 volts, but characteristic whitlockite peaks appeared above 325 volts, corresponding to temperatures above roughly 1000 degrees Celsius. Pushing to 400 volts proved counterproductive, as excessive thermal shock caused precursor decomposition and micro-explosions that weakened the signal. Pulse duration mattered just as much: at 325 volts, a one-millisecond pulse reached only about 345 degrees Celsius and produced no transformation, while ten milliseconds or more sustained temperatures near 1100 degrees Celsius, with peaks sharpening as duration increased to twenty milliseconds, indicating improved crystallinity.

The number of flashes proved to be a powerful dial for controlling crystal evolution. Repeated irradiation drove heating rates of about 43,000 kelvin per second and cooling rates of about 2,700 kelvin per second, thousands of times faster than conventional furnace treatment, which suppresses grain growth and phase separation. Transmission electron microscopy tracked the transformation shot by shot. After a single flash, particles around two micrometers across showed heterogeneous mixtures of calcium, magnesium, phosphorus, and oxygen. By ten shots, the elements had distributed more evenly, and by twenty shots the particles had fragmented and recrystallized into uniform rhombohedral whitlockite crystallites averaging below 200 nanometers. The researchers attribute this fragmentation to the explosive release of trapped water vapor, which increases surface area and accelerates ion diffusion between successive pulses.

The importance of the hydrated precursor emerged clearly from control experiments. When an anhydrous mixture of dicalcium phosphate, tricalcium phosphate, and magnesium hydroxide was flashed under identical conditions, X-ray photoelectron spectroscopy detected only phosphate bonding. The hydrated mixture, by contrast, yielded both phosphate and hydrogen phosphate components, the latter accounting for about 34 percent of the phosphorus signal and serving as the definitive fingerprint of whitlockite. Thermogravimetric analysis quantified the difference: the hydrated precursor released roughly four times more water than its anhydrous counterpart, and thermodynamic calculations confirmed that whitlockite stability expands dramatically as water partial pressure rises at high temperature.

The speed advantage is striking. Where conventional wet chemistry requires days of carefully orchestrated reactions, the IPL route delivers phase-pure nanocrystalline whitlockite within milliseconds of cumulative irradiation, with microwave-assisted and solid-state alternatives falling somewhere in between but struggling to reach the nanoscale. The team also confirmed biocompatibility, showing that eluates from the flash-synthesized material supported the viability of MC3T3-E1 osteoblast-like cells in standard assays, an early but essential signal of biological safety.

The researchers caution that comprehensive validation still lies ahead, including detailed in vitro osteogenic testing and in vivo bone regeneration studies. Even so, the demonstration that a bone mineral can be coaxed into existence in milliseconds, guided by nothing more than a flash, a carbon microheater, and a burst of confined steam, opens a genuinely new pathway for manufacturing calcium phosphate bioceramics. If the biological promise holds up, the humble water molecule trapped at a carbon interface may prove to be the unexpected key to the next generation of bone regeneration materials.

Subject of Research: Millisecond flash synthesis of whitlockite bioceramic via localized water vapor pressure

Article Title: Non‐Equilibrium Synthesis of Whitlockite Assisted by Localized H2O Vapor Pressure

Article References: Kim, M.-J., Lee, M., Jung, I.-H., Kang, S.-K., Jang, J.-S., & Han, H.-S. (2026). Non‐Equilibrium Synthesis of Whitlockite Assisted by Localized H 2 O Vapor Pressure. Advanced Science, 13(55), Article e76175. https://doi.org/10.1002/advs.76175

Image Credits: AI Generated

DOI: 10.1002/advs.76175

Keywords: whitlockite, calcium phosphate, bone regeneration, intense pulsed light, bioceramics, nanomaterials, hydrogen phosphate, carbon microheater, non-equilibrium synthesis, water vapor pressure, biomaterials, flash synthesis

The scaffold’s design reflects a growing recognition in biomaterials science that tumor removal and tissue reconstruction have traditionally been treated as separate clinical challenges. Surgeons excise the tumor, then wait—sometimes through multiple additional interventions—for the bone defect to heal, all while monitoring for local recurrence. The new scaffold attempts to collapse this timeline by embedding three complementary therapeutic functions into a single printed structure. Each component was chosen for a specific biochemical role, and together they form what the researchers describe as a catalytic-immune system working in concert with osteoinductive signaling.

At the heart of the antitumor function is a dopamine–manganese coordination nanozyme, abbreviated DM, which forms a mussel-inspired catalytic coating on the scaffold surface. The mussel-inspired chemistry is significant because polydopamine coatings adhere robustly to diverse substrates under mild aqueous conditions, allowing the nanozyme to be integrated without harsh coupling reagents that could damage the delicate biological cargo carried elsewhere in the scaffold. Nanozymes—engineered nanomaterials that mimic the catalytic activity of natural enzymes—have attracted intense interest because they combine enzyme-like reactivity with the stability, tunability, and manufacturability of synthetic materials.

The DM nanozyme behaves differently depending on the chemical environment it encounters, which is the key to its dual function. In the acidic milieu characteristic of tumor tissue, it exhibits peroxidase-like activity, catalyzing Fenton-type reactions that generate highly reactive hydroxyl radicals. These radicals attack tumor cells directly, while the nanozyme simultaneously depletes glutathione, the antioxidant molecule that cancer cells rely on to neutralize oxidative stress. The combined effect overwhelms the tumor cells’ redox defenses and induces oxidative stress–mediated cell death. This chemodynamic strategy exploits a vulnerability that is specific to the tumor microenvironment, so the lethal chemistry is triggered where the acidity marks malignant tissue rather than throughout the body.

Under physiological pH, however, the same nanozyme switches roles entirely. In the neutral conditions of healthy regenerating tissue, DM displays superoxide dismutase-like and catalase-like activities, the two enzymatic steps that together convert destructive superoxide radicals into water and oxygen. In this mode, the nanozyme scavenges reactive oxygen species and helps maintain redox homeostasis. That matters for bone repair because excessive reactive oxygen species are known to impair osteoblast function and drive the chronic inflammation that stalls fracture healing. By quenching oxidative stress at the defect site, the coating creates a biochemical environment in which bone-forming cells can operate, effectively turning the tumor-killing catalyst into a tissue-protective antioxidant once the malignant chemistry has been neutralized.

The second therapeutic arm of the scaffold is immunological. Encapsulated within the hydrogel are dendritic cell-derived exosomes loaded with a cyclic dinucleotide that acts as an agonist of STING, the stimulator of interferon genes pathway. STING signaling is a central hub of innate immunity: when activated, it prompts cells to produce type I interferons and other inflammatory mediators that recruit and activate cytotoxic T lymphocytes capable of hunting down tumor cells. Dendritic cells are the professional antigen-presenting cells of the immune system, and exosomes derived from them offer a natural delivery vehicle that can ferry their immunostimulatory cargo to target cells while evading rapid clearance. The scaffold’s hydrogel matrix provides sustained release of these Dex-CDN particles, prolonging the local immune activation window rather than delivering a single transient dose.

This local immune strategy addresses one of the most persistent fears after bone-metastatic tumor surgery: microscopic disease left behind at the resection margin. Catalytic therapy kills cells it can reach directly, but the STING agonist is intended to do something different—convert the surgical site itself into an immunological alert zone where the patient’s own adaptive immune system is primed against residual tumor cells. Combining chemodynamic cell killing with immune checkpoint-free immune activation is an increasingly popular concept in oncology research, because dying tumor cells release antigens that, in the presence of interferon signaling, can be presented to T cells to generate a systemic antitumor response.

The third arm of the scaffold is dedicated to rebuilding bone. The researchers crosslinked the hydrogel network with methacrylated osteogenic growth peptide, or OGP-MA. Osteogenic growth peptide is a naturally occurring short peptide found in bone and blood that stimulates osteoblast proliferation and bone formation. By modifying it with methacrylate groups, the team made it copolymerizable into the GelMA network, so the osteogenic signal is not simply adsorbed onto the surface where it would diffuse away quickly, but is covalently incorporated into the scaffold architecture. According to the study, OGP-MA triggers osteogenic differentiation through the BMP/Smad signaling pathway, one of the canonical cascades that drives mesenchymal stem cells toward the bone-forming lineage.

The choice of a 3D-printed sodium alginate/GelMA hydrogel as the carrier is itself a technical decision with clinical implications. Alginate contributes mechanical robustness and printability, while GelMA—a gelatin derivative bearing methacrylate groups that crosslink under light—offers cell-adhesive motifs and controllable degradation. Printing the scaffold allows its internal architecture and pore structure to be tailored to the geometry of the specific bone defect, an advantage over prefabricated implants when reconstructing irregular post-resection cavities. The hydrogel’s hydrated, soft matrix is also compatible with the encapsulated exosomes and peptide, protecting the biological cargo while allowing gradual release as the material degrades.

The integrated design—catalytic tumor ablation, STING-driven immunity, and OGP-driven osteogenesis within one printed implant—offers what the authors present as a promising strategy for localized tumor control and bone regeneration following resection of bone-metastatic tumors. The work was supported by funding from China’s National Key Research and Development Program, the National Science and Technology Major Project, the National Natural Science Foundation of China, and several regional research programs, and the animal experiments were approved by the Dongguan People’s Hospital Laboratory Animal Welfare and Ethics Committee. While the platform will require extensive further validation before clinical use, it illustrates a broader shift in biomaterials engineering: implants conceived not as inert scaffolds that merely occupy space, but as programmable microenvironments that sense where they are, choose their chemistry accordingly, and orchestrate the body’s own defenses and repair mechanisms in the critical weeks after surgery.

Subject of Research: A 3D-printed hydrogel scaffold combining catalytic antitumor therapy, STING-mediated immunity, and osteogenic peptide signaling for bone repair after tumor resection

Article Title: A catalytic-immune OGP peptide-crosslinked 3D-printed hydrogel scaffold for concurrent antitumor therapy and bone regeneration

Article References: He, J., Wu, J., Wang, L., Yin, S., Yu, K., Liu, Y., Xu, D., Ji, T., Gao, Y., Du, Y., Gao, X., Cai, L., Xie, C., & Lu, X. (2026). A catalytic-immune OGP peptide-crosslinked 3D-printed hydrogel scaffold for concurrent antitumor therapy and bone regeneration. Advanced Composites and Hybrid Materials. https://doi.org/10.1007/s42114-026-02048-3

Image Credits: AI Generated

DOI: 10.1007/s42114-026-02048-3

Keywords: 3D-printed hydrogel scaffold, bone metastasis, nanozymes, Fenton reaction, STING agonist, dendritic cell exosomes, osteogenic growth peptide, bone regeneration, chemodynamic therapy, GelMA, tumor microenvironment, BMP/Smad signaling

The scaffolds at the heart of the study are made of hydroxyapatite, a mineral chemically similar to natural bone, arranged as an orthogonal lattice of rods with pores between 100 and 400 micrometers wide. Implanted into mandibular bone defects in Yucatan minipigs, these structures invite new bone to grow into their macropores, and quantifying how much bone has infiltrated each scaffold is the key to comparing different lattice designs and biological additives. The problem is that bone and hydroxyapatite share nearly identical mineral composition, so their X-ray attenuation values overlap almost completely in micro-CT scans. Ingrown bone also overlaps in brightness with the surrounding soft tissue and noise. Manual labeling of the roughly 1,000 images per scaffold is prohibitively time consuming across studies involving tens of scaffolds, which is exactly where the U-Net convolutional neural network enters the picture.

The U-Net architecture, first introduced in 2015, remains a favorite in biomedical imaging because it delivers strong segmentation from small training sets. Its U-shaped design works like an autoencoder with a memory: an encoding path progressively shrinks the image while doubling its feature channels to detect patterns, a bottleneck connects the two halves, and a decoding path restores the original dimensions, with skip connections threading fine spatial detail from encoder to decoder at every level. The Illinois team used a four-level network starting with eight feature channels and reaching 128 at the bottleneck, ultimately classifying every pixel in a 512-by-512 patch as scaffold, bone, or background. Rather than inventing a new architecture, the researchers held the network constant and varied only the loss function, the mathematical rule that tells the model how wrong its predictions are during training.

Three loss functions were pitted against each other under identical conditions. Cross-entropy loss, the workhorse of classification, evaluates every pixel individually regardless of class balance. Soft Dice loss instead optimizes the overlap between prediction and ground truth, a strategy favored when one class, like bone, occupies only a small fraction of the image. A third, less common option called Accuracy loss directly rewards correct classification of the entire patch. The team trained each model for 1,000 epochs on 225 patches derived from 31 manually labeled images, using four NVIDIA V100 GPUs and confirming that all three losses converged without overfitting. A second expert annotator independently relabeled a subset to gauge human variability, finding a bone Dice score of 0.78 between annotators and an average difference in bone growth fraction of just 1.2 percentage points.

Then came the surprise. Standard evaluation metrics, the numbers researchers typically report to demonstrate that a segmentation model works, produced results that seemed catastrophic but were actually meaningless. Some patches scored a Dice coefficient of zero and a Precision of zero, values usually interpreted as total failure, yet visual inspection showed those patches were segmented perfectly well. The catch: those patches contained no bone in the ground truth at all. When the model predicted a handful of spurious bone pixels in a bone-free image, the Dice and Precision formulas collapsed to zero even though the biological error was negligible. Similar distortions plagued Recall, which tanked on patches where a few missed pixels represented a large fraction of a tiny bone area. Under extreme class imbalance, the familiar metrics were measuring the imbalance, not the model.

To escape this trap, the researchers invented an application-specific endpoint they call delta BGF: simply the difference between the bone growth fraction predicted by the model and the bone growth fraction in the ground truth. This is the number that actually matters for the science, because the entire purpose of segmenting the scans is to quantify bone regeneration and compare treatment groups. Bland-Altman analysis showed the systematic bias between predicted and true bone growth fraction was less than 1.5 percentage points for all three models, comparable to the disagreement between two human experts. When the team correlated the standard metrics against the absolute value of delta BGF, Accuracy emerged as the clear winner, with correlation coefficients reaching negative 0.8 for the Accuracy-loss model and negative 0.78 for the Dice model. A Steiger test confirmed Accuracy’s correlation was significantly stronger than those of Dice, Precision, and Recall in eight of nine comparisons, and bootstrap resampling across 10,000 samples showed the relationship was stable, with confidence intervals lying entirely below zero.

The loss function also shaped where the errors landed, which matters because different regions of the image carry different scientific weight. The Accuracy-loss model tended to overestimate bone, scattering false positives inside the scaffold boundary, precisely where the ingrown bone quantification happens. The cross-entropy and Dice models instead missed bone in the dense ring surrounding the scaffold, errors that are conveniently located outside the region of interest and can be corrected automatically, since scaffold pixels cannot legitimately exist beyond the scaffold boundary. Given this geography of mistakes, the cross-entropy model emerged as the recommended choice for future in vivo studies quantifying spatial variation in bone growth, combining clean class edges within the scaffold with correctable peripheral errors.

Robustness testing added another layer of confidence. The team created augmented test sets by rotating patches 15, 30, and 45 degrees, shifting contrast in both directions, and degrading resolution by factors of 0.66 and 0.5, simulating the natural variation in micro-CT scanning parameters and scaffold orientation. None of these perturbations produced a statistically significant change in Accuracy, Dice, Precision, Recall, or delta BGF. The systematic bias remained below 2.6 percentage points across all augmentations, with contrast changes producing the widest limits of agreement and rotation the narrowest, suggesting that intensity shifts stress the model more than orientation changes. For a field where scanning protocols differ between labs and even between experiments, this resilience means the trained models can plausibly be applied to new datasets without retraining from scratch.

Perhaps the most consequential result is biological rather than computational. Comparing against the group’s earlier in vivo studies, the smallest treatment differences those studies could detect were on the order of 8 to 20 percentage points in bone fraction, vastly larger than the 1.5 percentage point error of the AI segmentation. In other words, the model’s mistakes are too small to obscure genuine biological differences between scaffold designs, meaning future comparisons of bone regeneration should remain statistically sound. The study’s limitations are acknowledged candidly: the 54 test patches derive from only six images, so patch-level statistics treat clustered data as independent, and the authors frame their correlation findings as descriptive rather than confirmatory. Still, the message radiates well beyond bone scaffolds. Whenever deep learning is deployed to extract a quantitative measurement rather than a pretty picture, the evaluation metric should be the measurement itself. A model that aces the standard report card can still flunk the science, and a model that appears to fail it may be quietly doing excellent work.

Subject of Research: Evaluating U-Net deep learning segmentation of bone ingrowth in micro-CT images of hydroxyapatite scaffolds using loss functions and application-specific metrics

Article Title: Segmenting scaffolds with ingrown bone in micro-CT images: considerations of evaluation metrics and loss functions

Article References: Aboutaleb, S., Haug, N., Keni-McCray, P., McCray, A. R. C., Phillips, H., Sharping, S., Cohen, D., Norato, J., & Wagoner Johnson, A. (2026). Segmenting scaffolds with ingrown bone in micro-CT images: considerations of evaluation metrics and loss functions. Medical & Biological Engineering & Computing. https://doi.org/10.1007/s11517-026-03686-x

Image Credits: AI Generated

DOI: 10.1007/s11517-026-03686-x

Keywords: U-Net, semantic segmentation, micro-CT, bone regeneration, hydroxyapatite scaffold, loss functions, evaluation metrics, Dice coefficient, cross-entropy loss, Bland-Altman analysis, deep learning, biomedical imaging

Bone is not the static scaffold it appears to be on an X-ray. Throughout life, the skeleton undergoes continuous renewal through the coordinated activity of bone-forming osteoblasts, bone-resorbing osteoclasts, mechanosensing osteocytes, mesenchymal stem cells, immune cells and endothelial cells lining the vasculature. When this balance tips, the consequences are familiar and debilitating: osteoporosis, delayed fracture healing, and failed bone grafts. The Guangzhou team argues that ApoEVs sit at a previously underappreciated control point in this system, ferrying RNA molecules, proteins and lipids between the cell types that build and break down bone, and thereby shaping the communication networks that keep skeletal tissue in homeostasis.

Technically, ApoEVs are a heterogeneous category. The review distinguishes several subtypes based on size and biogenesis, including large apoptotic bodies, apoptotic microvesicles shed from the plasma membrane, apoptotic exosome-like vesicles, and smaller apoptotic small extracellular vesicles. What unites them is their origin in programmed cell death and their cargo: they encapsulate messenger RNAs, microRNAs, long noncoding RNAs and ribosomal RNAs, together with proteins and lipids that often reflect the identity of the parent cell. A vesicle released by a bone marrow mesenchymal stem cell carries a different molecular inventory than one shed by a mature osteoclast, and that identity matters for the message the vesicle delivers to its recipient.

Two signaling circuits dominate the review’s mechanistic analysis. The first is the RANKL/RANK/OPG axis, the central lever of osteoclast biology. RANKL, expressed on osteoblasts and osteocytes, binds RANK on osteoclast precursors and drives their differentiation into bone-resorbing giants, while osteoprotegerin acts as a decoy receptor that dampens the process. ApoEVs can modulate this axis from multiple directions, influencing the ratio of RANKL to OPG in the local microenvironment and thereby tuning how aggressively bone is broken down. The second circuit is the Wnt/β-catenin pathway, the master switch for osteoblast differentiation. When Wnt ligands engage their receptors, β-catenin accumulates and translocates to the nucleus, switching on genes such as RUNX2 and Osterix that commit stem cells to the bone-forming lineage. ApoEVs have been shown to carry Wnt pathway components and microRNAs that either amplify or suppress this cascade depending on their cargo.

The cargo story is where the biology becomes genuinely striking. In preclinical studies summarized by the review, apoptotic vesicles derived from mesenchymal stem cells delivered microRNAs that activated the AKT and ERK signaling cascades in recipient cells, promoting osteogenic differentiation marked by elevated alkaline phosphatase activity and expression of osteocalcin and bone sialoprotein. Vesicles from other sources carried insulin-like growth factor binding proteins, bone morphogenetic protein pathway components, or stanniocalcin 1, each steering recipient cells along distinct trajectories. Even the surface of the vesicle participates: the abundant phosphatidylserine on the outer leaflet of apoptotic membranes is recognized by receptors such as MerTK and TIM-4 on phagocytes, linking vesicle uptake to the same engulfment machinery that clears dying cells during normal tissue turnover.

Immune regulation emerges as a third pillar. Macrophage-derived apoptotic vesicles and T cell-derived vesicles can shift the inflammatory tone of the bone microenvironment, and the review highlights interactions with the STING pathway, a cytosolic DNA sensor that drives inflammatory signaling when activated. By modulating tumor necrosis factor alpha, interleukins and cyclooxygenase-2 signaling, ApoEVs appear to help resolve inflammation after injury, creating a permissive environment for regeneration. This osteoimmunological dimension matters clinically, because excessive inflammation is a hallmark of osteoporotic bone loss and a major obstacle to fracture healing and implant integration.

The translational implications are already being tested in animal models. In studies of critical-sized bone defects, scaffolds loaded with mesenchymal stem cell-derived ApoEVs accelerated regeneration, with the vesicles promoting both new bone formation and angiogenesis through vascular endothelial growth factor signaling. In ovariectomized rodents, the standard model of postmenopausal osteoporosis, ApoEV-based treatments improved bone microarchitecture and partially reversed the resorption-heavy imbalance. Vesicles derived from dental pulp stem cells and periodontal ligament stem cells have shown promise in periodontal and craniofacial repair, while platelet-derived and red blood cell-derived apoptotic vesicles have been explored for their regenerative and immunomodulatory properties. Mature osteoclast-derived vesicles, intriguingly, appear to feed back on osteoblasts, suggesting that even the bone-destroying cells contribute building materials to the renewal cycle.

What makes ApoEVs attractive as therapeutic vehicles is structural as much as chemical. Their lipid bilayer protects fragile RNA cargo from degradation by serum nucleases, their phosphatidylserine-rich surface promotes uptake by target cells, and their size allows them to penetrate the extracellular matrix of bone tissue. The review describes engineering strategies that exploit these properties: surface functionalization with the aspartic acid-serine-serine peptide to confer bone-targeting ability, incorporation into gelatin methacryloyl hydrogels or poly(lactic-co-glycolic acid) scaffolds for local, sustained delivery, and preconditioning of parent cells with agents such as strontium or 1,25-dihydroxyvitamin D3 to load vesicles with pro-osteogenic cargo before they are harvested.

Significant hurdles remain before ApoEVs reach the clinic. The review notes that standardization of isolation and characterization protocols is still immature, that the heterogeneity of vesicle subpopulations complicates dose definition, and that scalable production under good manufacturing practice conditions has yet to be demonstrated for skeletal applications. Questions about biodistribution, immunogenicity across donors, and the long-term fate of vesicle cargo in recipients also await rigorous answers. The authors frame these as the field’s next frontier rather than disqualifying obstacles, pointing out that the same challenges confronted and were largely resolved for the broader extracellular vesicle field now advancing through early clinical trials.

The conceptual shift, however, may prove as important as any therapy. For decades, apoptosis was taught as a one-way street ending in silent disposal. The Guangzhou review makes the case that the dying cell’s final act is communicative: it packages its regulatory contents into vesicles that instruct neighboring stem cells, immune cells and vascular cells on how to rebuild. In the skeleton, where the stakes include osteoporosis affecting hundreds of millions of people worldwide, that reframing turns cellular death from a passive endpoint into an active resource, and it positions apoptotic extracellular vesicles as candidates for a new generation of regenerative treatments built from the body’s own demolition byproducts.

Subject of Research: Roles of apoptotic extracellular vesicles in bone remodeling and regeneration

Article Title: Emerging roles of apoptotic extracellular vesicles in bone remodeling: mechanisms and applications

Article References: Wu, S., Chen, Z., Yuan, Q., Chen, H., Zhang, B., & Lin, T. (2026). Emerging roles of apoptotic extracellular vesicles in bone remodeling: mechanisms and applications. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08921-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08921-5

Keywords: apoptotic extracellular vesicles, bone remodeling, osteoporosis, bone regeneration, RANKL/RANK/OPG axis, Wnt/beta-catenin pathway, mesenchymal stem cells, osteoblasts, osteoclasts, osteoimmunology, extracellular vesicles, bone tissue engineering

The clinical problem is formidable. Bone defects caused by trauma, infection, tumour resection and congenital abnormalities are common, and while small injuries heal spontaneously, defects exceeding the local regenerative capacity, so-called critical-sized defects, often fail to close on their own. Autologous bone grafting remains the gold standard because it delivers osteogenic cells, inductive growth factors and a conductive matrix simultaneously, but it is limited by donor-site morbidity and restricted availability. Allografts are more available yet carry risks of immune rejection, infection and variable efficacy. What is needed, the review contends, are regenerative strategies that remain stable and reproducible inside the messy, inflamed microenvironment of a real defect.

Bioprinting offers an unusual degree of control over that environment. Unlike conventional fabrication, printing allows multiple materials, cells and bioactive signals to be arranged in three dimensions with defined pore architecture, compositional gradients and localised mechanical properties. Composite bioinks built from printable hydrogels such as gelatin methacryloyl (GelMA), alginate and hyaluronic acid methacrylate can be blended with inorganic phases including calcium phosphate, hydroxyapatite, beta-tricalcium phosphate and bioactive glass, balancing printability with an osteogenic milieu. Crucially, these same components release ions and present surface chemistry that shape the earliest host immune recognition of the implant, making the printer a tool for immunology as much as for structural engineering.

The biological rationale comes from the now well-established field of osteoimmunology. Bone repair unfolds in overlapping phases: an inflammatory phase dominated by neutrophils and pro-inflammatory M1-like macrophages that clear debris and pathogens; a proliferative phase in which macrophages shift toward reparative M2-like states, releasing factors such as TGF-beta and VEGF that recruit mesenchymal stem cells and drive angiogenesis; and a remodeling phase in which osteoblasts and osteoclasts, governed by the RANKL/OPG axis, convert woven bone into mechanically adapted lamellar bone. Simply suppressing the early inflammatory burst, the review stresses, can starve the repair process of the very signals that initiate cell recruitment and vascularisation. The goal instead is controlled, resolvable inflammation.

Material composition is one of the three main levers the authors identify. Strontium-substituted calcium silicate hydrate nanowires incorporated into a GelMA bioink, for example, released Sr, Ca and Si ions that nudged macrophages toward a repair-associated phenotype while supporting bone marrow stromal cell differentiation, producing substantial regeneration in rat critical-sized calvarial defects. Silicon-substituted calcium phosphate combined with methacrylated bone-derived extracellular matrix showed a striking temporal immune transition in vivo, from early pro-inflammatory activation to later anti-inflammatory resolution, linked to suppression of p38 MAPK signalling. Zinc-releasing ZIF-8 metal-organic framework particles delivered the anti-inflammatory polyphenol luteolin alongside Zn2+ ions, integrating immunomodulation, antioxidation and antibacterial action in a single printed construct.

Geometry itself can be immunologically active. Using digital light processing, researchers fabricated hydroxyapatite scaffolds identical in composition but differing only in pore size, and found that 600-micrometre pores best regulated macrophage behaviour through IFN-beta and HIF-1alpha-related signalling while improving vascularisation and bone formation. Even curvature matters: beta-tricalcium phosphate scaffolds engineered with negative Gaussian curvature suppressed macrophage Ras-MAPK/HIF-1alpha signalling and increased secretion of BMP-2 and VEGF, promoting vascularised bone ingrowth in a rabbit segmental defect model. Melt electrowriting adds another dimension, with ordered PCL microfibres and calcium phosphate coatings steering macrophages toward repair-associated states via PI3K/AKT and cAMP-PKA signalling, demonstrating that physical microarchitecture can substitute for exogenous drugs.

The most sophisticated strategies deliver bioactive cargo in stage-matched sequences. One printed system used coaxial bioprinting with sequential crosslinking to release interferon-gamma first, preserving the early inflammatory activation needed for repair initiation, before Laponite-derived magnesium and silicon ions gradually drove macrophages toward a reparative state, ultimately enhancing vascularised bone regeneration in calvarial defects. Interleukin-4 delivered from graphene oxide/black phosphorus nanointerfaces promoted CD206-positive macrophages while the materials themselves supported angiogenesis and osteogenesis. Exosome-based approaches add further nuance: macrophage-derived vesicles from mixed functional states outperformed those from purely M2-like macrophages in stimulating osteogenic signalling, underscoring the review’s warning that the simplified M1/M2 dichotomy cannot capture the continuum of immune states that real healing involves.

The authors are candid about translational hurdles. Every added component, whether living cells, recombinant cytokines, exosomes or decellularised matrix, increases batch variability, manufacturing complexity and regulatory burden. Sterilisation methods can silently alter hydrogel mechanics and even macrophage gene expression, while endotoxin contamination at low levels can confound the interpretation of a material’s intrinsic immunological effects. Degradation kinetics must be synchronised with tissue ingrowth: too fast and the scaffold loses support prematurely, too slow and the foreign-body response persists. The review advocates defining critical quality attributes that reflect immunomodulatory potency, not just scaffold geometry and compressive strength, and pursuing standardised platforms with patient-specific variation confined to a validated design space.

Looking forward, the field is moving toward spatiotemporal and even intelligent regulation. Microenvironment-responsive hydrogels that release therapeutic ions only under pathological acidity or oxidative stress, four-dimensional printing that changes scaffold architecture over time, and machine-learning frameworks that optimise bioink composition against immune as well as mechanical endpoints all feature in the review’s roadmap. Pathology-specific design receives particular emphasis: infected defects need preserved antimicrobial inflammation before resolution, diabetic defects require correction of hyperglycaemia-driven oxidative stress, and aged or osteoporotic bone demands restoration of senescence-impaired immune function rather than generic osteogenic stimulation. The overarching message is that the next generation of bone scaffolds should not simply contain more ingredients, but should speak the immune system’s own temporal language, guiding inflammation, vascularisation and remodeling in the order that nature intended.

Subject of Research: Immunoregulatory biomaterials and 3D bioprinting strategies for bone regeneration

Article Title: Advances in 3D bioprinting of immunoregulatory biomaterials for bone regeneration

Article References: Wang, X., & Zhang, A. (2026). Advances in 3D bioprinting of immunoregulatory biomaterials for bone regeneration. Materials Today Bio, 41, Article 103714. https://doi.org/10.1016/j.mtbio.2026.103714

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103714

Keywords: 3D bioprinting, bone regeneration, osteoimmunology, macrophage polarization, bioinks, GelMA, biomaterials, critical-sized bone defects, exosomes, cytokine delivery, scaffold architecture, tissue engineering

Organoid technology has reshaped regenerative medicine by moving beyond flat cell culture toward self-organized three-dimensional microtissues that better reproduce native tissue architecture and function. Unlike conventional two-dimensional cultures, bone organoids preserve cell-cell communication, cell-matrix interactions, lineage patterning, and extracellular matrix remodeling within a spatially relevant environment. Recent years have seen skeletal organoid systems expand to include bone marrow-like, trabecular-like, callus-like, and woven-bone-like constructs, with matrix engineering and biofabrication enabling tighter control of geometry and maturation. Yet the field still confronts key barriers, including inadequate vascularization, immature mechanics, diffusion limitations in larger constructs, and the absence of standardized bioactive programming. In this study, the term bone organoids refers specifically to bone marrow stromal cell-derived three-dimensional osteogenic microtissues that reproduce selected features of bone formation, including cell-cell interaction, matrix production, and mineral deposition, rather than fully vascularized or marrow-containing bone equivalents.

Achyranthes bidentata, the botanical source of a traditional Chinese medicine, emerged as an attractive candidate for biofunctionalizing such constructs. Pharmacognostic studies identify multiple bioactive constituents in the plant, including polysaccharides, saponins, steroids, and related small molecules, and toxicology work suggests a favorable safety profile at therapeutic doses. Experimental evidence supports a direct role in skeletal repair: AB saponins promote osteogenic differentiation of bone marrow stromal cells through the ERK/MAPK pathway, osteoblast studies show enhanced proliferation and Runx2-associated osteogenic activity after treatment, and purified polysaccharide fractions exhibit in vitro osteogenic activity. In parallel, AB regulates the resorptive arm of bone remodeling, with prior studies demonstrating suppression of osteoclastogenesis through inhibition of RANKL signaling and osteoprotective effects in vivo through regulation of the RANKL/RANK/OPG axis. This dual anabolic and anti-resorptive potential is precisely the type of combined cue needed for functional bone regeneration, yet until now AB research and organoid engineering had largely progressed in parallel.

The research team, led by Chenxing Lu and colleagues, designed a four-stage workflow: dose screening of AB in rat bone marrow-derived mesenchymal stromal cells, generation and characterization of AB-bone organoids, evaluation in a critical-sized calvarial defect model, and an exploratory retrospective clinical analysis of AB exposure in tibial fracture healing. The botanical material was authenticated by macroscopic and microscopic examination according to the Pharmacopoeia of the People’s Republic of China, with voucher specimens deposited at the Institute of Chinese Materia Medica. Dried roots were decocted with distilled water, filtered, concentrated, and lyophilized to an 18.5 percent extraction yield, then characterized by high-performance liquid chromatography fingerprinting to establish batch traceability before any biological testing began.

Dose screening revealed a concentration-dependent osteopromotive window. Bone marrow stromal cells exposed to graded concentrations from 0 to 400 micrograms per milliliter showed good cytocompatibility at low and intermediate doses, with cell viability and proliferative activity rising steadily up to 200 micrograms per milliliter, the concentration that produced peak alkaline phosphatase activity and Alizarin Red S-detected mineralization. At 400 micrograms per milliliter, the proliferative benefit was attenuated, indicating that the effect was concentration dependent rather than linearly cumulative. Quantitative PCR confirmed that AB markedly upregulated the osteogenic program, increasing expression of Col1a1, Runx2, Opn, and Ocn. Mechanistic experiments using PD98059, a selective ERK/MAPK pathway inhibitor, showed that AB increased ERK1/2 phosphorylation and that blocking the pathway partially attenuated AB-enhanced alkaline phosphatase activity and mineralized matrix formation, implicating ERK/MAPK signaling as a partial, though not exclusive, contributor to the herb’s pro-osteogenic effect.

The pivotal step came when the team incorporated AB into bone organoid culture. Single-cell suspensions of stromal cells were seeded into ultra-low-attachment plates to form compact spheroids over three days, then embedded in growth factor-reduced Matrigel and cultured in osteogenic medium for 28 days, with 200 micrograms per milliliter AB added throughout maturation. Live/dead staining showed both groups remained viable, but AB-treated organoids displayed more widespread calcein-AM signal and reduced propidium iodide incorporation. Quantitative analysis demonstrated that AB-treated organoids achieved a larger cross-sectional area, suggesting accelerated tissue assembly and volumetric growth. Histological and matrix analyses confirmed the functional differences: AB-bone organoids exhibited stronger Alizarin Red S, alkaline phosphatase, and collagen type I staining, indicating enhanced calcium deposition, osteogenic enzyme activity, and extracellular matrix production, while immunofluorescence revealed more organized F-actin architecture and stronger Runx2 expression consistent with heightened osteogenic lineage activation.

Head-to-head comparison of monolayer cultures, untreated bone organoids, and AB-bone organoids revealed a stepwise enhancement in osteogenic output, with AB-bone organoids achieving the highest levels of enzymatic activity and matrix mineralization, accompanied by increased protein expression of COL-I, Runx2, and OPN and higher viability. The decisive test, however, came in vivo. In a critical-sized 5-millimeter calvarial defect model in adult rats, animals receiving AB-bone organoids showed more extensive defect bridging and denser mineralized tissue on micro-CT reconstructions at 12 weeks than those receiving untreated organoids or no implant. Quantitative analysis confirmed the most favorable bone microarchitecture in the AB-bone organoid group, with increased bone volume fraction, bone mineral density, trabecular thickness, and trabecular number, together with reduced trabecular separation. Histology showed greater bone fill and more organized collagen deposition, and immunohistochemistry revealed more abundant COL-I, OPN, and OCN-positive matrix within the regenerative area.

To explore clinical relevance, the team conducted a retrospective cohort study at Taizhou Hospital of Traditional Chinese Medicine, screening 126 consecutive tibial fracture patients operated on between January 2022 and December 2024, of whom 40 met eligibility criteria and were divided into 20 receiving oral AB beginning one month after surgery for six weeks and 20 receiving standard care. Baseline characteristics were well balanced between groups. Postoperative AB administration was associated with substantially shorter mean radiographic healing time of 3.8 versus 4.9 months, higher modified Radiographic Union Scale scores at final follow-up of 14.1 versus 12.3, lower pain scores of 1.3 versus 2.6 on the visual analogue scale, and superior lower-extremity function scores of 72.5 versus 65.2. Serial radiographs showed earlier callus formation and advanced remodeling in AB-treated patients, although the proportion achieving union by six months did not differ significantly.

The authors are careful to delineate the boundaries of these findings. The animal experiment evaluated localized implantation of AB-preconditioned organoids, while the clinical cohort evaluated systemic oral administration with entirely different pharmacokinetics, so the human data provide only indirect, hypothesis-generating support rather than evidence for the clinical feasibility of organoid implantation. Retrospective design cannot fully account for unmeasured confounding, and factors such as fracture severity, fixation characteristics, and rehabilitation compliance were not uniformly available. The calvarial model is non-load-bearing, vascularization was not directly quantified, the specific bioactive constituents responsible remain unidentified, and the ERK/MAPK experiments were conducted only in monolayer cells. Even so, the conceptual advance is considerable: a traditional osteoactive botanical factor has been repurposed as a developmental instruction for bone organoids, upgrading the therapeutic unit from isolated cells or soluble factors to an implantable living osteogenic microtissue, and defining a promising direction for biologically instructed bone regeneration that now awaits testing in load-bearing models, vascularized constructs, and eventually dedicated clinical trials.

Subject of Research: Achyranthes bidentata-functionalized bone marrow stromal cell-derived bone organoids for enhanced bone defect repair

Article Title: Achyranthes bidentata –functionalized bone organoids enhance bone defect repair

Article References: Lu, C., Qin, X., Lin, Z., Han, S., Ding, P., Xu, L., Zheng, X., Hu, B., Chen, F., & Wu, D. (2026). Achyranthes bidentata–functionalized bone organoids enhance bone defect repair. Materials Today Bio, 41, Article 103716. https://doi.org/10.1016/j.mtbio.2026.103716

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103716

Keywords: bone organoids, Achyranthes bidentata, bone regeneration, critical-sized defects, mesenchymal stromal cells, ERK/MAPK signaling, traditional Chinese medicine, calvarial defect model, fracture healing, osteogenesis, tissue engineering, Materials Today Bio

The starting point for the study was a deceptively simple observation problem. Dental follicle stem cells, or DFSCs, are considered strong candidates for periodontal tissue engineering because they are accessible, expandable in culture, and naturally inclined toward the lineages needed to rebuild tooth-supporting structures. Yet like all adult stem cells, they accumulate damage with passaging and environmental stress. The team therefore asked a question that sits at the intersection of stem cell biology and regenerative dentistry: what molecular changes accompany DFSC senescence, and can any of them be reversed before the cells are transplanted into a patient?

To answer it, the researchers pushed human DFSCs into senescence in two distinct ways. One cohort was subjected to oxidative stress, mimicking the inflammatory environment of a diseased periodontal pocket, while another was driven into replicative senescence through repeated rounds of cell division. Gene-expression profiling and protein analyses then revealed a dramatic pattern: IGFBP5 expression collapsed in both models, falling by more than fivefold under oxidative stress and by a striking 69-fold during replicative senescence. The senescent cells simultaneously displayed elevated reactive oxygen species, impaired viability and migration, and weakened osteogenic differentiation, confirming that the aging process was compromising exactly the functions a therapeutic cell population would need.

What happened when the researchers restored IGFBP5 is the heart of the study. Reintroducing the protein counteracted several hallmarks of senescence at once: senescence-associated molecular changes diminished, reactive oxygen species levels dropped, cell-cycle activity improved, and markers of bone formation rebounded in the stressed cells. “We found that restoring IGFBP5 could counter several features of stem cell senescence,” says Prof. Liu. “Improvements in cell survival and bone-forming ability suggested that IGFBP5 may help preserve the regenerative function of DFSCs during aging.” In other words, a single binding protein appeared to act as a gatekeeper for the regenerative identity of these cells.

The mechanistic trail then led the team into Wnt signaling territory, one of the most consequential regulatory networks in developmental and stem cell biology. Gene-expression analysis pointed to the non-canonical Wnt pathway, rather than the classical Wnt/beta-catenin arm, as the relevant branch. IGFBP5 overexpression reduced levels of WNT5B and the transcription factor c-Jun, while canonical pathway components remained largely unchanged. Follow-up experiments sharpened the causal picture: adding WNT5B externally weakened the bone-forming benefits conferred by IGFBP5 and increased a cellular senescence marker, whereas blocking WNT5B partially rescued both the senescent phenotype and the osteogenic defects of replicatively aged cells. Together, the data suggest that IGFBP5 sustains the function of aging DFSCs at least partly by suppressing WNT5B-related signaling, positioning the IGFBP5-WNT5B axis as a regulatory circuit with real therapeutic leverage.

Translating a molecular discovery into a usable therapy requires more than a protein target; it requires a delivery vehicle that can keep engineered cells alive in the harsh environment of a periodontal defect. The Sichuan team addressed this with a composite scaffold called Gel-vHA@oe-DFSC. The system weaves three components together: a gelatin methacryloyl, or GelMA, hydrogel that provides a biocompatible three-dimensional matrix; vinyl-functionalized nanohydroxyapatite, a bone-mimetic mineral phase that supports osteoconductivity; and DFSCs genetically engineered to overexpress IGFBP5. In laboratory testing, the hydrogel supported cell survival under oxidative stress, promoted healthy cell spreading, and enhanced osteogenic activity, indicating that the material itself was actively contributing to the regenerative environment rather than merely holding cells in place.

The decisive test came in rats with experimentally induced periodontitis. When the IGFBP5-overexpressing cell-laden hydrogel was applied to periodontal defects, the treated animals showed improved alveolar bone quality, with measurable increases in bone mineral density and bone volume fraction. Histological examination of the regenerated tissue revealed less inflammation and better collagen organization than in controls, suggesting that the treatment did not simply deposit mineral but fostered structurally more faithful repair. “Our results suggest that rejuvenating therapeutic stem cells before delivery may be more effective than simply transplanting untreated cells,” says Prof. Liu. “The scaffold also provides a way to support these modified cells at the periodontal defect site while they promote local tissue repair.”

The implications of the study extend well beyond dentistry. Cellular senescence is a central obstacle in regenerative medicine generally, limiting the efficacy of stem cell therapies for bone, cartilage, skin, and other tissues in older patients. If IGFBP5 proves to be a generalizable marker and modulator of stem cell aging, it could serve a dual role: as a molecular indicator used to quality-control cell products before transplantation, and as a target for pre-treatment rejuvenation strategies. The findings also add momentum to the growing field of hydrogel-based cell delivery, where biomaterials are increasingly designed to do more than carry cargo, actively participating in the signaling dialogue that determines whether transplanted cells survive, integrate, and differentiate.

The authors are careful to frame the work as a foundation rather than a finished therapy. The experiments were conducted in human cell lines in vitro and in a rat model, and the researchers note that additional studies are needed in cells derived from older patients and in larger animal models before any clinical application can be contemplated. Questions about the long-term behavior of IGFBP5-overexpressing cells, the optimal dosing of the pathway modulation, and the safety of genetic engineering in therapeutic contexts all remain open. Still, the study is notable for the completeness of its arc, moving from a senescence phenotype, through gene-expression discovery and mechanistic validation, to a biomaterial delivery system and an in vivo demonstration of efficacy.

For the millions of people whose teeth are loosened by age-related periodontal bone loss, the prospect of regenerating the damaged foundation rather than merely slowing its decline remains a distant but increasingly credible goal. What this study contributes is a concrete molecular handle, IGFBP5 and its suppression of WNT5B signaling, and a practical delivery platform that pairs rejuvenated stem cells with a bone-mimetic hydrogel. By demonstrating that treating the cells before they are transplanted can outperform simply transplanting them, the Sichuan team has articulated a principle that could reshape how regenerative dentistry, and perhaps regenerative medicine more broadly, thinks about the aging of its most important raw material. The work was supported by the National Natural Science Foundation of China and the Sichuan Science and Technology Program, and the authors declare no competing interests.

Subject of Research: IGFBP5-mediated rejuvenation of dental follicle stem cells for periodontal bone regeneration

Article Title: A stem cell pathway offers a new route to periodontal bone regeneration

Article References: A stem cell pathway offers a new route to periodontal bone regeneration. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: periodontitis, dental follicle stem cells, IGFBP5, WNT5B, cellular senescence, bone regeneration, hydrogel, GelMA, nanohydroxyapatite, regenerative medicine, Sichuan University, non-canonical Wnt pathway

The central insight behind the work is that bone repair is not simply a materials problem but an ecological one. When a scaffold is implanted, the first cells to arrive are macrophages, the immune system’s resident first responders. Depending on the chemical signals they encounter, these macrophages polarize into two broad phenotypes: the M1 state, which drives inflammation and can stall healing, and the M2 state, which releases growth factors that recruit stem cells, build blood vessels, and lay down new matrix. Conventional implants often leave this immune decision to chance. The new scaffold is designed to tip the balance deliberately, converting the inevitable inflammatory response into a constructive one without any drugs, external stimulation, or electronic control.

To achieve this, the researchers drew directly on the composition and microstructure of natural bone. Using a hydrothermal process—essentially growing crystals in a hot, pressurized aqueous solution—they formed a coating of calcium titanate on the struts of three-dimensional printed porous titanium alloy scaffolds. Calcium titanate is chemically akin to the mineral phase of bone and is known to bond readily with living tissue. Crucially, the coating was doped with trace amounts of bioactive metal ions and engineered with a micro- and nano-scale gradient morphology, meaning its texture transitions across length scales the way natural bone surfaces do, from rough micro-features down to nanocrystalline detail. This hierarchical topography matters because cells on surfaces sense features at exactly these dimensions, and their behavior—adhesion, spreading, migration, differentiation—shifts in response.

The functional surface works through two coupled mechanisms. First, the micro/nano topography itself provides physical cues that guide cell behavior, a phenomenon well established in biomaterials science but here integrated into a load-bearing printed implant. Second, the trace ions incorporated into the calcium titanate coating are released slowly and sustainably into the local microenvironment. Rather than flooding the tissue with a burst of soluble factors that fades within days, the scaffold acts like a reservoir, dosing the surrounding cells continuously as the coating gradually exchanges ions with body fluid. The result, according to the authors, is a surface that modulates its own microenvironment—hence the term self-regulated in the study’s title.

What makes the study particularly striking is the breadth of the biological response it documents. Most bone implant research focuses narrowly on osteogenesis, the formation of new bone. This team evaluated the scaffolds both in vitro, with cells cultured on their surfaces, and in vivo, in animal defect models, and assessed not only bone formation but also angiogenesis—the sprouting of new blood vessels—and neurogenesis, the ingrowth of nerve fibers. The vascular component is well appreciated: without blood supply, newly formed bone cannot survive, and the deep pores of a large scaffold are notorious dead zones for vessel penetration. The neural component is newer territory. Nerve fibers are increasingly recognized as active participants in bone remodeling, releasing neuropeptides that regulate both osteoblasts, the bone-forming cells, and osteoclasts, the bone-resorbing cells. A scaffold that simultaneously supports vessels and nerves is, in effect, rebuilding the entire neurovascular infrastructure that living bone depends on.

Beneath these observable outcomes, the researchers mapped the molecular machinery driving the effect. Their analysis points to the simultaneous activation of two signaling axes: PPAR, the peroxisome proliferator-activated receptor pathway, and the PI3K-Akt-mTOR cascade, a central growth-and-metabolism pathway shared across many cell types. Together, these pathways pushed infiltrating macrophages toward the M2 phenotype—the pro-healing, anti-inflammatory state. In practical terms, the scaffold’s surface chemistry and topography appear to reprogram the immune response at its source, so that the cells arriving first at the implant set a regenerative tone for everything that follows. This immunomodulatory framing reflects a broader shift in the biomaterials field, where the goal is no longer to make surfaces that the immune system tolerates, but surfaces that recruit the immune system as an ally.

The technical achievement of growing such a coating in situ on a printed titanium lattice should not be understated. Three-dimensional printed porous titanium alloys are already used clinically in spinal fusion, hip revision surgery, and maxillofacial reconstruction, prized for their stiffness matching and the interconnected porosity that lets tissue grow in. But post-printing surface functionalization is delicate: any treatment must not clog the pores, weaken the struts, or introduce brittleness. Hydrothermal growth is attractive precisely because it is a low-temperature, solution-based method that conformally coats complex geometries, following every curve and corner of the printed architecture. The gradient morphology of the resulting layer suggests the crystal growth was tuned across scales, producing a surface that is rough at the micron level and textured at the nanoscale—conditions that favor protein adsorption and cell attachment.

The implications for patients are considerable. Implant failure due to poor osseointegration—the direct structural bond between bone and implant surface—remains a costly and painful problem, particularly in patients with diabetes, osteoporosis, or compromised vasculature, where healing is slow and inflammation is chronic. A scaffold that actively accelerates vascularization and calibrates the immune response could expand the pool of patients for whom large bone reconstructions succeed. Because the functionalization is a surface treatment rather than a change to the bulk metal, it could in principle be retrofitted onto existing printing workflows without redesigning the implants themselves. The authors position the work as a foundation for intelligent implants—devices that manage their own healing process rather than depending on the body to overcome their presence.

Caveats remain, as they always do at this stage of translation. The study’s biological evaluation, while spanning cell culture and animal models, precedes the clinical trials that any new implant surface must eventually face. Long-term durability of the ion-releasing coating under years of mechanical loading, the behavior of the surface in infected or osteoporotic bone beds, and the scalability of hydrothermal processing for commercial manufacturing are all questions that future work must answer. The research was conducted by a large multidisciplinary team led by corresponding authors Hai Huang, Hao Wu, and Zheng Guo, with support from China’s National Key Research and Development Program and the National Natural Science Foundation of China, and the article is open access, allowing clinicians and materials scientists worldwide to examine the data in full.

Still, the conceptual leap is hard to miss. For half a century, biomaterials have been judged by how quietly they disappear into the body’s background. This work argues for a different standard: that an implant’s surface can be an active participant in healing, sensing nothing yet regulating everything through nothing more than geometry and chemistry. A printed titanium lattice, dressed in a bone-like mineral skin that speaks the language of macrophages, endothelial cells, neurons, and osteoblasts, may represent the clearest demonstration yet that the smartest implant is not the one packed with electronics, but the one designed to let biology do what it already knows how to do—provided the surface gives it the right instructions.

Subject of Research: Bioactive surface-functionalized 3D-printed titanium scaffolds that self-regulate immune, neurovascular, and osteogenic bone repair

Article Title: Self-regulated immune-neurovascular bone repair scaffold via functional surface features

Article References: Yu, D., Tang, Z., Yang, T., Guo, S., Bao, S., Li, C., Wu, Q., Chen, C., Liu, Y., Li, X., Huang, H., Wu, H., & Guo, Z. (2026). Self-regulated immune-neurovascular bone repair scaffold via functional surface features. Advanced Composites and Hybrid Materials. https://doi.org/10.1007/s42114-026-02095-w

Image Credits: AI Generated

DOI: 10.1007/s42114-026-02095-w

Keywords: bone regeneration, 3D-printed titanium scaffold, calcium titanate coating, macrophage polarization, M2 phenotype, angiogenesis, neurogenesis, osseointegration, PPAR signaling, PI3K-Akt-mTOR pathway, bioinspired materials, immunomodulation

Tendon-bone insertion injuries, which occur where soft tendon tissue anchors into hard bone, are among the most frequently encountered injuries in daily life and sports. Their clinical burden is growing annually, and restoring normal physiological function remains remarkably difficult. The reason lies in the anatomy: the tendon-bone junction is a graded transition zone that includes a specialized fibrocartilage layer, and unlike many tissues, it cannot regenerate itself faithfully after injury. Instead, the body fills the gap with disorganized scar tissue that has low biomechanical strength. That weakness translates directly into high postoperative re-rupture rates, making rapid, high-quality regeneration an urgent challenge in orthopedics, sports medicine, and tissue engineering.

The quality of tendon-bone healing depends heavily on how well the fibrocartilage layer regenerates at the interface, and macrophages, the versatile immune cells that flood any wound site, orchestrate much of that process. In the early phase of healing, M1-polarized macrophages dominate, secreting pro-inflammatory factors such as IL-1β and IL-6 that intensify local inflammation and recruit fibroblasts to the damaged site. Later, macrophages shift toward the M2 phenotype, releasing anti-inflammatory signals like IL-10 and Arg1 that dampen inflammation and promote tissue reconstruction. Previous work has shown that this transition from a pro-inflammatory to an anti-inflammatory microenvironment is crucial for moving from the inflammatory phase into the proliferative phase of repair, and that biologically inducing early M2 aggregation at the interface actively improves healing outcomes.

What makes the new study distinctive is its focus on macrophage metabolism. M2 macrophages rely on oxidative phosphorylation and fatty acid oxidation (FAO) for their energy supply, whereas activation of PPAR signaling and its regulatory genes increases FAO capacity. The research team, led by Xiaojun Ma and colleagues, hypothesized that if a compound could push macrophage metabolism toward FAO and oxidative phosphorylation, it would favor M2 polarization and thereby improve tendon-bone healing. Didymin was a natural candidate: earlier reports had documented its purgative, anti-inflammatory, and antioxidant properties, and prior metabolic tracing experiments had revealed that the compound enhances FAO rather than glycolysis. Crucially, didymin had already been shown to modulate the M1/M2 balance by converting pro-inflammatory M1-like macrophages into anti-inflammatory M2-like ones, without altering baseline M2 polarization.

To test the hypothesis, the researchers established a mouse model of tendon-bone healing by surgically severing the Achilles tendon near the calcaneal bone, scraping away the residual fibrocartilaginous layer, drilling a bone channel, and suturing the tendon stump back to the bone, a procedure that mimics the changes seen after rotator cuff reconstruction. Thirty-six male C57BL/6J mice were randomly assigned to six groups: a sham-operated control, an untreated model group, three didymin dose groups receiving 1, 2, or 4 milligrams per kilogram per day by oral gavage, and a positive-control group receiving the drug disulfiram at 50 milligrams per kilogram per day. Treatment began one day after surgery and continued daily for four weeks, with all protocols approved by the animal ethics committee of the People’s Hospital of Ningxia Hui Autonomous Region.

The structural results were striking. Micro-computed tomography scanning showed that high-dose didymin produced new bone volume at the interface comparable to that seen in the positive-control group, with significant increases in bone volume fraction, bone surface, trabecular number, and bone mineral density, along with significantly reduced trabecular separation compared with the untreated model group. Histological staining revealed that model-group animals suffered from disorganized collagen fibers, consolidated fibroblast nuclei, necrotic areas, and inflammatory cell infiltration at the junction, all of which were attenuated by didymin treatment. Serum biochemistry told a matching story: levels of osteocalcin, alkaline phosphatase, and calcium, all markers of bone formation activity, rose significantly in the treated animals.

Fibrocartilage regeneration, the critical determinant of healing quality, also improved. Safranin-O/fast green staining showed localized absence of the cartilage layer and abnormal chondrocyte proliferation in untreated mice, defects that didymin largely corrected. Immunofluorescence assays demonstrated that expression of the cartilage markers Sox9 and Collagen II, which dropped sharply at the injured interface, was significantly restored by the compound. The researchers also measured increased expression of TGF-β1 and TGF-β3, growth factors known to drive chondrogenesis and fibrocartilage formation, further supporting the conclusion that didymin actively promotes regeneration of the specialized transition tissue rather than merely reducing inflammation.

Flow cytometry and molecular profiling of the healing tissue revealed the immune mechanism at work. Untreated model mice showed elevated levels of F4/80-positive CD86-positive M1 macrophages and elevated IL-1β and IL-6 mRNA, while didymin administration at all three doses reduced these pro-inflammatory indicators. Medium and high doses simultaneously raised the abundance of F4/80-positive CD206-positive M2 macrophages and increased expression of Arg1 and IL-10. In parallel cell experiments using bone marrow-derived macrophages, didymin significantly reduced CD86 expression under M1-polarizing conditions and boosted levels of acetyl-CoA, the FAO enzymes Cpt1a and ACS, and the PPAR pathway proteins PPAR-γ and RXRA, indicating a metabolic reprogramming toward fatty acid oxidation.

The team then ran a decisive validation experiment using pharmacological blockers. When the PPAR-γ antagonist GW9662 or the fatty acid oxidation inhibitor etomoxir was added to didymin-treated M1 macrophages, the compound’s effects were substantially reversed: acetyl-CoA levels, CD206-positive M2 populations, and anti-inflammatory Arg1 and IL-10 expression all fell, while CD86-positive M1 populations and pro-inflammatory IL-1β and IL-6 rose again. This loss-of-function evidence strongly suggests that didymin drives macrophage polarization toward the M2 phenotype specifically by promoting the PPAR signaling-mediated FAO pathway, which in turn supports tendon-bone healing.

The authors acknowledge important limitations that temper immediate clinical translation. No biomechanical testing was performed, the antagonist and inhibitor experiments were conducted only in cell culture rather than in living animals, and all mice received local penicillin injections postoperatively, which could theoretically interact with didymin’s anti-inflammatory and antibacterial properties. Only male mice were studied, and sex is known to influence inflammatory responses, bone metabolism, and tendon healing, so verification in female animals is needed. The mouse Achilles model also cannot fully reproduce the biomechanics, vascular supply, and stress conditions of human rotator cuff attachment sites. Even so, the study lays a concrete foundation for didymin as a candidate therapy, linking a dietary flavonoid, immune cell metabolism, and musculoskeletal regeneration in a single mechanistic chain that future research can now build upon.

Subject of Research: The role of didymin in promoting tendon-bone healing through PPAR-mediated fatty acid oxidation and macrophage M2 polarization

Article Title: Didymin may Enhance Tendon‐Bone Healing Partly by Promoting PPAR‐Mediated Fatty Acid Oxidation and Macrophage M2 Polarization

Article References: Ma, X., Shen, J., Ma, J., Li, H., Li, Y., & Wan, J. (2026). Didymin may Enhance Tendon‐Bone Healing Partly by Promoting PPAR‐Mediated Fatty Acid Oxidation and Macrophage M2 Polarization. Immunity, Inflammation and Disease, 14(9), Article e70485. https://doi.org/10.1002/iid3.70485

Image Credits: AI Generated

DOI: 10.1002/iid3.70485

Keywords: didymin, tendon-bone healing, macrophage polarization, M2 macrophages, PPAR signaling, fatty acid oxidation, fibrocartilage, Achilles tendon, rotator cuff, bone regeneration, inflammation, natural compounds